Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after
utero exposure to opioids. Sublingual buprenorphine shows promise as a new treatment in NAS.
This trial will investigate the safety and tolerability of sublingual buprenorphine in
infants exposed to both opioids and benzodiazepines in utero or with exposure of opioids in
those who are breastfeeding.